Introduction
Epidemiological surveys have shown that hypercholesterolaemia is associated with an increased risk of developing ischaemic heart disease (IHD)"2. Recent trials have demonstrated that reduction of plasma cholesterol in patients with hypercholesterolaemia reduces this risk. In Oslo a 47% decrease in myocardial infarction and sudden death was achieved by lipid-lowering dietary advice and reduction in cigarette smoking3. In the United States Lipid Research Clinics Trial, cholestyramine therapy produced a 19% fall in coronary heart disease deaths and nonfatal myocardial infarction. The incidence of other cardiovascular events (angina, new positive exercise tests and coronary bypass surgery) was also reduced4. In this trial the reduction in coronary heart disease risk was proportional to the degree of cholesterol-lowering achieved5.
The benefit of cholesterol reduction is likely to be greatest in those at greatest risk. In familial hypercholesterolaemia, a common autosomal dominant condition characterized by tendon xanthomata and premature vascular disease, this risk of IHD is particularly high. A study of heterozygotes performed 16 years ago6 suggested that nearly a quarter of the men with this condition might die before the age of 50. At that time relatively few patients received effective lipid-lowering therapy.
The recent experience of the Oxford Lipid Clinic, where energetic treatment of hyperlipidaemia has been recommended for the past 10 years, has been reviewed to assess the current prevalence of IHD in patients with FH. The cardiovascular risks of severe hypertriglyceridaemia (plasma triglyceride >5 mmol/1) are unknown, and we have therefore included in this report our experience of the prevalence of IHD in these patients.
Methods
Patients: Between 1981 and 1984, 94 patients were entered on to a hyperlipidaemia register in Oxford. They represented all eligible patients (see below) referred to the Lipid Clinic during the years 1975-1984. Thirty-three patients were discovered through other affected family members. Fourteen had the diagnosis made following a myocardial infarction. Nine presented with angina pectoris and 2 with intermittent claudication. Eight were referred from dermatology clinics. In the remaining 28 patients hyperlipidaemia was discovered during investigations for some other complaint.
Three categories were defined ( The Royal Society of Medicine (definite familial hypercholesterolaemia) -a total cholesterol of > 6.7 mmol/l in a child (< 16 years), and total cholesterol >7.5 mmol/l or low-density lipoprotein (LDL) cholesterol >4.9 mmol/l in an adult together with the presence of tendon xanthomas in the patient or a first or second-degree relative; Group 2 (possible familial hypercholesterolaemia) -a total cholesterol of > 6.7 mmol/l in a child, and total cholesterol >7.5 mmol/I or LDL cholesterol > 4.9 mmol/l in an adult with either a family history of myocardial infarction (below the age of 50 years in a second-degree relative or below the age of 60 years in a first-degree relative) or a family history of raised cholesterol levels (>7.5 mmol/l in a first or second-degree relative); Group 3 (severe hypertriglyceridaemia) -a 14-hour fasting triglyceride level of >5 mmol/l on at least two occasions other than during an episode of acute uncontrolled diabetes mellitus. At registration a questionnaire was used to obtain details of family history and past medical historyincluding previous myocardial infarction, smoking habits and alcohol intake. Angina and claudication were assessed using the World Health Organization questionnaires7. The history was supplemented by review of the case notes. Height and weight were measured and used to calculate a body mass (BMI) in kg/m2. A blood pressure (BP) recording was made after 5 minutes supine rest using a mercury sphygmomanometer. Hypertension was diagnosed if registration BP was > 160 mmHg systolic/ > 95 mmHg (diastolic fifth phase) or if the patient was receiving antihypertensive medication. Details of peripheral pulses were recorded.
Plasma cholesterol and triglycerides were measured using automated enzymatic methods. Cholesterol in the lipoprotein fractions was measured after precipitation8"9. Pretreatment values ofplasma cholesterol and triglyceride were recorded. Post-treatment levels were calculated as the mean of all available estimations obtained while the patient was receiving lipid-lowering therapy. Lipid levels at the time of registration were recorded as current lipid levels.
Electrocardiography: A standard 12 lead ECG was recorded (Hewlett-Packard Cardiograph) in 79 patients (40 in Group 1, 24 in Group 2 and 15 in Group 3). Traces were classified using the Minnesota code7. The following major abnormalities were noted: Q or Q/S complexes (1:1-1), ST depression (4:1), T-wave inversion (5:1-2).
Exercise electrocardiography: This was performed in patients over the age of 20 years provided there was no contraindication (e.g. unstable angina). Eight patients refused this investigation. None of these had clinical evidence of ischaemic heart disease. Exercise was performed on a treadmill (Quinton Instrument Co, USA). Speed and incline were increased every 3 minutes according to a Bruce exercise protocol modified by the addition of a warm-up stage (gradient 5%, speed 2.9 kph). ECG was monitored continuously and a modified 12 lead recording made every minute on an ink-jet recorder (Siemens Mingograph 62). The tests were symptom-limited. The Coronary artery disease: Other risk factors for coronary artery disease were: cigarette smoking (9 patients) and hypertension (5 patients). Thirteen (46%) patients had evidence of IHD (Table 3) . Coronary arteriography was performed in 5 patients. All had significant coronary artery disease (3 triple vessel, 2 double vessel). The data presented here illustrate the potential value of a clinical case series, especially when it includes a representative sample of patients who have all received regular follow up and in whom the condition is not readily amenable to study in a formal clinical trial.
